Trailing-twelve-month (TTM) revenue is $668.47 Million with a year-over-year growth of +25.82%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $143,823,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $160,764,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $173,933,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $189,948,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $668,468,000 |
Current P/S: $2,986,752,978 market capitalization ÷ $668,468,000 TTM revenue = 4.47x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $189.95M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-19T00:16:01.560Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Ocs Heart Product | $14M | $18M | N/A | N/A | N/A | N/A |
| Ocs Liver Product | $5M | $2M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-28 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD |
|---|---|---|---|---|
| GERMANY | $1M | N/A | N/A | N/A |
| Non Us And Uk | N/A | $6M | $8M | N/A |
| Other Countries | $4M | N/A |
$668.47M
$668.47 Million
+25.82%
vs. $531.29M a year ago (TTM)
+86.12%
5 Year compound annual growth rate
1 Year
+25.82%
3 Year
+64.15%
5 Year
+86.12%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $605.49M | +$163.95M | +37.13% |
| 2024 | $441.54M | +$199.92M | +82.74% |
| 2023 | $241.62M | +$148.16M | +158.53% |
| 2022 | $93.46M | +$63.20M | +208.83% |
| 2021 | $30.26M | +$4.62M | +18.03% |
| 2020 |
TTM Growth
+25.82%
3-Year CAGR
+64.15%
5-Year CAGR
+86.12%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 34 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-19T00:16:01.560Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Ocs Lung Product | $6M | $11M | N/A | N/A | N/A | N/A |
|---|
| Product | N/A | N/A | $79M | $176M | $274M | $372M |
|---|
| Service Revenue | N/A | N/A | $14M | $66M | $168M | $233M |
|---|
| $880,000 |
| UNITED STATES | $16M | $19M | $22M | $8M |
|---|
| $25.64M |
| +$2.04M |
| +8.62% |
| 2019 | $23.60M | +$10.59M | +81.33% |
| 2018 | $13.02M | +$5.33M | +69.38% |
| 2017 | $7.68M | +$1.48M | +23.77% |
